Use of zoledronic acid (ZA) and interleukin-2 (IL-2) to activate and expand V{gamma}9V{delta}2 T cells for therapeutic use in patients with metastatic renal cell carcinoma (mRCC)

14607 Background: Approximately 3–6% of human peripheral blood lymphocytes express the γδ T cell receptor (TCR). The majority of these cells express the Vδ2 TCR variable segment associated with the...